Regular aspirin use may do more harm than good, study warns

Can an aspirin a day keep the doctor away? New research, part of the EU-funded BIOMED (Biomedicine and health) programme, shows it can't all the time. The researchers have discovered that although regular use of aspirin can reduce the rate of non-fatal heart attacks or stroke by around 12%, there is a 33% increase in the risk of internal bleeding in people with no history of relevant disease (primary prevention). The findings are published in The Lancet journal.

Professor Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at Oxford University in the UK headed the study, which found that general guidelines supporting the regular use of aspirin in all healthy individuals are unjustified.

"Drug safety really matters when making recommendations for tens of millions of healthy people," he is quoted as saying by The Daily Mail. "And for healthy people, there is not enough evidence to suggest that the benefits of long-term aspirin exceed the risks by a suitable margin," he added.

"Current guidelines largely ignore any differences in bleeding risk, and recommend that aspirin be used widely for primary prevention in those at moderately raised risk of coronary heart disease," the study reads. "It has also been suggested that, since age is a major determinant of the risk of coronary heart disease, daily aspirin should be started in all people above a specific age, either alone or in combination with other drugs."

The researchers, who are members of the 'Antithrombotic Trialists' (ATT) collaboration, evaluated data from more than 95,000 people participating in 6 randomised clinical trials that examined primary prevention with the use of aspirin.

Based on the results, the risk of serious vascular events fell from 0.57% to 0.51% each year because of aspirin treatment, but the risk of major bleeds rose from 0.07% to 0.10% each year. According to the researchers, this indicates that aspirin is not, in fact, a foolproof method for primary prevention.

"In patients who are at high risk because they already have occlusive vascular disease, long-term antiplatelet therapy (e.g. with aspirin) reduces the yearly risk of serious vascular events by about a quarter," the study reads. "This decrease typically corresponds to an absolute reduction of about 10 to 20 per 1,000 in the yearly incidence of non-fatal events, and to a smaller, but still definite, reduction in vascular death."

In the secondary prevention studies, which targeted patients taking aspirin to prevent a repeat attack, the researchers found that aspirin cuts the risk of serious vascular events by about 20%. The reductions in risk were similar for men and women in both sets of trials.

The alternative to primary prevention, say the researchers, is to postpone starting long-term aspirin treatment until some evidence of occlusive vascular disease, which affects arteries and leads to distal arterial insufficiency and ischaemia, is seen.

"The main disadvantage of deferral is that the first manifestation of disease might be a disabling or fatal event, but the main advantage is that it could avoid decades of slightly increased risk of cerebral haemorrhage or major extracranial bleeding," the research shows.

Further trials are already in progress, according to the team.

For more information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer's elranatamab receives FDA and EMA filing a…

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) ...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...